Riskpilot← Back to searchSign inGet full accessNorrapotek AB
ABDissolvedOrg 5591287163Economic activity was not specified by tax authority · NACE 0000Est. 20170 employees
Revenue 2024
SEK 0
EBITDA margin
—
+93% vs 2023
Equity ratio
78.8%
Financial strength
Net profit 2024
SEK -980
+100% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -980 | +93% |
| Net profit | SEK -980 | +100% |
| Total assets | SEK 411K | -49% |
| Equity | SEK 324K | -55% |
| Employees | 0 | — |
Legal name
Norrapotek AB
Org number
5591287163
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
10 oktober 2017
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Jern, David Bengt Olof Firman tecknas av styrelsen Firman tecknas ensam av Jern, David Bengt Olof
Company purpose
Bolaget skall bedriva konsultverksamhet inom ledarskap, marknadsföring och ekonomi och försäljning. Ävensom äga och förvalta såväl fast som lös egendom, aktier och andra värdepapper samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | −1 | −26 | −15 | −1 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 0 | −1 | −26 | −15 | −1 |
| Net financials | — | 22 | — | −849 | — |
| Profit before tax | 0 | 21 | — | — | −1 |
| Tax | −0 | −0 | — | — | — |
| Net profit | 0 | 21 | −26 | −864 | −1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 95 | 165 | 1 164 | 812 | 411 |
| Equity | 95 | 115 | 89 | 725 | 324 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 0 | 50 | 75 | 87 | 87 |
| Total debt | — | 50 | 75 | 87 | 87 |
EBITDA margin
-98000.0%
This company
15.8%
Market median
-620353% vs market
20202024
Equity ratio
78.8%
This company
38.2%
Market median
+106% vs market
20202024
Return on equity
-0.3%
This company
18.4%
Market median
-102% vs market
20202024
Net profit margin
-98000.0%
This company
8.1%
Market median
-1209977% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bioswed Scientific AB
Norrapotek AB Board members of Norrapotek AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Magnus Froste | Deputy Board Member | 0 companies |
| David Bengt Olof Jern | Board of Directors | 0 companies |